Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:36:46 2024-04-23 am EDT			5-day change	1st Jan Change
88.85 ^EUR	+0.77%		+2.37%	-1.01%

Apr. 23	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Apr. 23	Sector Update: Health Care	MT

SANOFI : Gets a Buy rating from JP Morgan

December 01, 2021 at 09:41 am EST

Already positive, the research from JP Morgan and its analyst Richard Vosser still consider the stock as a Buy opportunity. The target price remains set at EUR 105.

Latest news about Sanofi

Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 23	MT
Sector Update: Health Care	Apr. 23	MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business	Apr. 23	MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News	Apr. 23	RE
CAC40: up sharply, back over 8100 pts	Apr. 23	CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5	Apr. 23	CF
CAC40: closes in on 8,100, well supported by W-Street	Apr. 23	CF
CAC40: up slightly after encouraging PMI figures	Apr. 23	CF
Sanofi: positive phase III data in IPT	Apr. 23	CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia	Apr. 23	MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial	Apr. 23	DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims	Apr. 23	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team	Apr. 22	MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer	Apr. 22	MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million	Apr. 22	MT
SANOFI : Gets a Buy rating from UBS	Apr. 22	ZD
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla...	Apr. 19
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 19	MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 18	MT
Sanofi to overhaul US operations of vaccines, cut jobs	Apr. 18	RE

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

88.85 EUR

Average target price

107.8 EUR

Spread / Average Target

+21.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-1.01%	117B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Gets a Buy rating from JP Morgan

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals